Key Takeaways
- Genentech has halted the phase 2 trial of flizasertib, a RIPK1 inhibitor, due to unsatisfactory interim results.
- The drug aimed to address acute kidney injury post-heart surgery but failed to show significant clinical benefits.
- This decision highlights ongoing challenges in developing effective RIPK1 inhibitors, with multiple past failures in the field.
Genentech Halts Flizasertib Trial
Genentech has decided to cease its phase 2 trial of the RIPK1 inhibitor flizasertib (GDC-8264) following an analysis that indicated the drug was unlikely to meet its primary endpoint. This marks a significant setback for Genentech and the broader landscape of RIPK1 inhibitor research.
The decision was confirmed by a company spokesperson and reflects interim data that suggested the study would not demonstrate a marked clinical benefit. Initially, flizasertib was in development to treat acute kidney injury, a frequent complication after heart surgeries, including coronary artery bypass, valve replacements, and aortic procedures, where blood flow to the kidneys is compromised.
The phase 2 trial, which began in January 2025, involved 67 patients. It was designed as a randomized, placebo-controlled study, focusing on the percentage of patients experiencing persistent complications within 90 days following a surgery-induced kidney injury. Unfortunately, flizasertib was not expected to deliver on this primary efficacy measure.
Flizasertib was first introduced to the scientific community last fall through a paper published in the Journal of Medicinal Chemistry, where Genentech’s researchers praised its target selectivity and drug-like qualities suitable for daily oral administration.
This setback is compounded by the broader struggles faced by the RIPK1 inhibitor field, which has seen numerous attempts to bring an effective medication to market, yet continues to lack a successful approval. The RIPK family, which stands for receptor-interacting serine/threonine-protein kinase, includes enzymes crucial for managing inflammation and cell death.
History shows this is not a new challenge; GSK first started clinical research on a RIPK1 inhibitor back in 2014 but later downgraded it for further investigation. Another candidate, which was meant for prostate cancer, was eliminated from GSK’s pipeline in 2019. Similarly, French pharmaceutical giant Sanofi, which engaged in a partnership with Denali Therapeutics in 2018, has also retrenched from investing in RIPK1 inhibitors due to series of phase 2 failures. Its last Denali-related RIPK1 project was halted at the start of 2025.
Eli Lilly is another key player reconsidering its involvement in RIPK1 drugs. After a $960 million collaboration deal with Rigel Pharmaceuticals in 2021, Lilly had to reassess the partnership, particularly its central nervous system-focused aspects. Nevertheless, Rigel’s candidate, ocadusertib (now known as LY3871801), continues to be studied for rheumatoid arthritis.
In a surprising turn, researchers in Korea have identified a previously approved drug, phensuximide—originally formulated for epilepsy—as a potential candidate for inhibiting RIPK1’s inflammatory properties, suggesting there may still be unexplored opportunities in this field.
The landscape for RIPK1 inhibitors remains fraught with challenges, with flizasertib’s withdrawal marking yet another chapter in an ongoing narrative of scientific exploration and hurdles in drug development.
The content above is a summary. For more details, see the source article.